We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Effect of Oxymetholone in Refractory Anemia

Arch Intern Med. 1964;113(5):721-729. doi:10.1001/archinte.1964.00280110101020.
Text Size: A A A
Published online


Until recently, the prognosis of refractory anemia could be summarized in the following terms: "Marrow aplasia cannot be reversed by any known means. Supportive therapy with transfusions and antibiotics is usually necessary and, in milder cases, may prolong life until spontaneous recovery of marrow function occurs." 29 With the exception of the rare cases in which splenectomy improved the clinical and hematological picture, the course of the disease was but slightly modified by therapy.17,21,26 The present outlook is brighter since androgenic hormone therapy has been introduced in this condition.31 The testosterone derivatives used (methyltestosterone; testosterone cyclopentylate, enanthate, and propionate; and fluoxymesterone) have several disadvantages consisting of bone-maturating and virilizing actions; some of the derivatives are orally inactive or produce liver damage. In view of this, it seemed advisable to investigate, in patients with medular insufficiency, the therapeutic action of oxymetholone (2-hydroxymethylene-17α-methyldihydrotestosterone), an anabolic hormone with less virilizing activity.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.